secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001672688-25-000082
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Absci Reports Q3 2025 Results, Advances ABS-201 and ABS-101 Programs
--------------------------------------------------------------------

- Reported interim Phase 1 data for ABS-101 (anti-TL1A) showing extended half-life with no serious adverse events.
- Accelerated initiation of Phase 1/2a trial for ABS-201 in androgenetic alopecia to December 2025.
- Expanding ABS-201 strategy to endometriosis, targeting Phase 2 start in Q4 2026 and proof-of-concept in H2 2027.
- Cash, cash equivalents, and marketable securities totaled $152.5 million as of Sept 30, 2025, funding operations into H1 2028.
- Net loss was $28.7 million for Q3 2025, compared to $27.4 million in Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/0001672688-25-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/absc-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001672688-25-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer